ArticleDrug design, development and therapy2026
A Pharmacist-Driven Closed-Loop Stewardship Model of Meropenem: Impact on Stability and Efficacy in Neurosurgery Patients.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the impact of a pharmacist-driven closed-loop stewardship model on meropenem stability and therapeutic efficacy in neurosurgical patients with hospital-acquired pneumonia (HAP). Patients and Methods: An interrupted time series study enrolled neurosurgical patients treated with meropenem for HAP. The patients from October 2019 to December 2021 were retrospectively collected as the control group, whereas the patients were prospectively enrolled from January 2022 to March 2025 as the intervention group. The intervention featured optimized drug preparation, prioritized administration, rapid specimen processing, real-time therapeutic drug monitoring and dynamic dose adjustments. Steady-state trough concentrations (C Results: A total of 227 patients was included (control group: n = 102; intervention group: n = 125). The intervention group demonstrated a significantly higher median C Conclusion: The closed-loop stewardship model effectively improved meropenem target concentration attainment by systematically reducing drug loss through degradation and metabolism. This optimized exposure profile correlated with improved eradication rates of Gram-negative sensitive bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.